The most frequent liver tumor in children is hepatoblastoma (HB), which derives from
embryonic parenchymal liver cells or hepatoblasts. Hepatocellular carcinoma (HCC), which …

Hepatoblastoma is a malignant embryonal tumor with multiple differentiation modes and is
the clearest liver malignancy in children. However, little is known about genetic and …

Background Axitinib is an oral small molecule that inhibits receptor tyrosine kinases vascular
endothelial growth factor receptors 1 to 3. A phase 1 and pharmacokinetic (PK) trial …

Aim: To compare the cytotoxic effects of 11 anticancer agents against VX2 and HepG2 cells
in order to establish candidate drugs that can be tested preclinically on VX2 tumor model for …

Increasing gap junction activity in tumor cells provides a target by which to enhance
antineoplastic therapies. Previously, several naturally occurring agents, including all-trans …

Background Treatment outcome of children with pediatric hepatocellular carcinoma (pHCC)
is poor. Therefore, we evaluated the tyrosine kinase inhibitor sorafenib in a model of pHCC …

Background: Sorafenib has recently been shown to reduce tumour growth in
hepatoblastoma (HB) xenografts. The effect of a combined administration with cytostatic …

Background Hepatoblastoma (HB) is the most common primary, malignant pediatric liver
tumor in children. The treatment results for affected children have markedly improved in …

In order to find efficient new antitumor drugs, a series of novel pyrimidine derivatives
containing urea moiety were designed and synthesized, and the antitumor activity of four …

There are few treatment options for patients with unresectable or refractory hepatoblastoma
which has failed to respond to the standard treatment. The rarity of the disease and lack of …